CSF2 and neoplasm: While data has yet to be published from clinical trials monitoring immunosuppressive monocytes in those receiving CAR-T cell therapies, reports from animal model studies suggest that rodent MDSCs are expanded after treatment with CAR-T cells in a GM-CSF dependent fashion, and that this limited the anti-tumor activity of the infused cells (86).